Phase 1b: ciforadenant,100 mg BID orally, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg q3 weeks.Phase 2 dose-expansion.TRAE (>Grade 3): 34% (of n=50 evaluable cases).Common TRAE in all grades: fatigue, rash, AST and ALT increase, hyponatremia.One patient died of ICI overlap syndrome.Overall: acceptable safety from triplet therapy. The gene discussed is GPT; the disease is connective tissue disorder.